In vivo release of adrenal catecholamines in rats by fusaric acid

K. Rácz, Otto Kuchel, Nguyen T. Buu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We studied the effect of fusaric acid, an inhibitor of dopamine β-hydroxylase (DβH), on plasma and peripheral tissue catecholamine (CA) content and on urinary excretion of CA in the rat. We found that fusaric acid treatment resulted in a rapid decline of adrenal epinephrine (E) and norepinephrine (NE) and an increase of adrenal dopamine (DA); the kidney and heart NE and DA contents were affected in a pattern similar to that of the adrenals. In contrast, the E concentrations in the kidneys and heart were markedly elevated after a single intraperitoneal dose of fusaric acid (100 mg/kg); the maximum response was observed at 60 min, when kidney E increased from 9.3 ± 4.4 to 101 ± 24 pmol/g tissue and heart E in both atrium and ventricle rose from 92 ± 8 to 607 ± 85 pmol/g tissue and from 70 ± 4 to 632 ± 50 pmol/g tissue, respectively. In addition, a large increase of CA (predominantly of E) was found in the plasma of treated rats, where E, NE and DA were 27. 6.6 and 2.7 times higher that control values, respectively. The excretions of urinary E and NE were also significantly elevated during treatment. Fusaric acid-treated bilaterally adrenalectomized rats did not exhibit any increase in plasma, heart and kidney E concentrations. The results suggest that fusaric acid stimulates adrenal CA release in vivo, resulting in large increases of the main adrenal CA, E in peripheral tissues, plasma and urine. The decline in the adrenal E content is thus not only due to its decreased synthesis but also increased release.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalEuropean Journal of Pharmacology
Volume109
Issue number1
DOIs
Publication statusPublished - Feb 12 1985

Fingerprint

Fusaric Acid
Catecholamines
Dopamine
Norepinephrine
Kidney
Mixed Function Oxygenases
Epinephrine
Urine

Keywords

  • Adrenal catecholamine release
  • Dopamine β-hydroxylase inhibitors
  • Fusaric acid

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

In vivo release of adrenal catecholamines in rats by fusaric acid. / Rácz, K.; Kuchel, Otto; Buu, Nguyen T.

In: European Journal of Pharmacology, Vol. 109, No. 1, 12.02.1985, p. 1-7.

Research output: Contribution to journalArticle

Rácz, K. ; Kuchel, Otto ; Buu, Nguyen T. / In vivo release of adrenal catecholamines in rats by fusaric acid. In: European Journal of Pharmacology. 1985 ; Vol. 109, No. 1. pp. 1-7.
@article{53facf1b7beb41c8b6135190f89ae410,
title = "In vivo release of adrenal catecholamines in rats by fusaric acid",
abstract = "We studied the effect of fusaric acid, an inhibitor of dopamine β-hydroxylase (DβH), on plasma and peripheral tissue catecholamine (CA) content and on urinary excretion of CA in the rat. We found that fusaric acid treatment resulted in a rapid decline of adrenal epinephrine (E) and norepinephrine (NE) and an increase of adrenal dopamine (DA); the kidney and heart NE and DA contents were affected in a pattern similar to that of the adrenals. In contrast, the E concentrations in the kidneys and heart were markedly elevated after a single intraperitoneal dose of fusaric acid (100 mg/kg); the maximum response was observed at 60 min, when kidney E increased from 9.3 ± 4.4 to 101 ± 24 pmol/g tissue and heart E in both atrium and ventricle rose from 92 ± 8 to 607 ± 85 pmol/g tissue and from 70 ± 4 to 632 ± 50 pmol/g tissue, respectively. In addition, a large increase of CA (predominantly of E) was found in the plasma of treated rats, where E, NE and DA were 27. 6.6 and 2.7 times higher that control values, respectively. The excretions of urinary E and NE were also significantly elevated during treatment. Fusaric acid-treated bilaterally adrenalectomized rats did not exhibit any increase in plasma, heart and kidney E concentrations. The results suggest that fusaric acid stimulates adrenal CA release in vivo, resulting in large increases of the main adrenal CA, E in peripheral tissues, plasma and urine. The decline in the adrenal E content is thus not only due to its decreased synthesis but also increased release.",
keywords = "Adrenal catecholamine release, Dopamine β-hydroxylase inhibitors, Fusaric acid",
author = "K. R{\'a}cz and Otto Kuchel and Buu, {Nguyen T.}",
year = "1985",
month = "2",
day = "12",
doi = "10.1016/0014-2999(85)90533-3",
language = "English",
volume = "109",
pages = "1--7",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - In vivo release of adrenal catecholamines in rats by fusaric acid

AU - Rácz, K.

AU - Kuchel, Otto

AU - Buu, Nguyen T.

PY - 1985/2/12

Y1 - 1985/2/12

N2 - We studied the effect of fusaric acid, an inhibitor of dopamine β-hydroxylase (DβH), on plasma and peripheral tissue catecholamine (CA) content and on urinary excretion of CA in the rat. We found that fusaric acid treatment resulted in a rapid decline of adrenal epinephrine (E) and norepinephrine (NE) and an increase of adrenal dopamine (DA); the kidney and heart NE and DA contents were affected in a pattern similar to that of the adrenals. In contrast, the E concentrations in the kidneys and heart were markedly elevated after a single intraperitoneal dose of fusaric acid (100 mg/kg); the maximum response was observed at 60 min, when kidney E increased from 9.3 ± 4.4 to 101 ± 24 pmol/g tissue and heart E in both atrium and ventricle rose from 92 ± 8 to 607 ± 85 pmol/g tissue and from 70 ± 4 to 632 ± 50 pmol/g tissue, respectively. In addition, a large increase of CA (predominantly of E) was found in the plasma of treated rats, where E, NE and DA were 27. 6.6 and 2.7 times higher that control values, respectively. The excretions of urinary E and NE were also significantly elevated during treatment. Fusaric acid-treated bilaterally adrenalectomized rats did not exhibit any increase in plasma, heart and kidney E concentrations. The results suggest that fusaric acid stimulates adrenal CA release in vivo, resulting in large increases of the main adrenal CA, E in peripheral tissues, plasma and urine. The decline in the adrenal E content is thus not only due to its decreased synthesis but also increased release.

AB - We studied the effect of fusaric acid, an inhibitor of dopamine β-hydroxylase (DβH), on plasma and peripheral tissue catecholamine (CA) content and on urinary excretion of CA in the rat. We found that fusaric acid treatment resulted in a rapid decline of adrenal epinephrine (E) and norepinephrine (NE) and an increase of adrenal dopamine (DA); the kidney and heart NE and DA contents were affected in a pattern similar to that of the adrenals. In contrast, the E concentrations in the kidneys and heart were markedly elevated after a single intraperitoneal dose of fusaric acid (100 mg/kg); the maximum response was observed at 60 min, when kidney E increased from 9.3 ± 4.4 to 101 ± 24 pmol/g tissue and heart E in both atrium and ventricle rose from 92 ± 8 to 607 ± 85 pmol/g tissue and from 70 ± 4 to 632 ± 50 pmol/g tissue, respectively. In addition, a large increase of CA (predominantly of E) was found in the plasma of treated rats, where E, NE and DA were 27. 6.6 and 2.7 times higher that control values, respectively. The excretions of urinary E and NE were also significantly elevated during treatment. Fusaric acid-treated bilaterally adrenalectomized rats did not exhibit any increase in plasma, heart and kidney E concentrations. The results suggest that fusaric acid stimulates adrenal CA release in vivo, resulting in large increases of the main adrenal CA, E in peripheral tissues, plasma and urine. The decline in the adrenal E content is thus not only due to its decreased synthesis but also increased release.

KW - Adrenal catecholamine release

KW - Dopamine β-hydroxylase inhibitors

KW - Fusaric acid

UR - http://www.scopus.com/inward/record.url?scp=0021911749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021911749&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(85)90533-3

DO - 10.1016/0014-2999(85)90533-3

M3 - Article

C2 - 3996464

AN - SCOPUS:0021911749

VL - 109

SP - 1

EP - 7

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -